MANUFACTURING CHEMIST – EU supply chain regulation: what will it mean for companies attending CPHI?

Ahead of her session on “Manufacturing Excellence” at CPHI Frankfurt (1–3 November), Elisabeth Stampa, President of Medicines for Europe, along with Adrian van den Hoven, Director General of Medicines for Europe, map out the impact of EU supply chain regulation on pharma companies in an exclusive article for Manufacturing Chemist
Open

Digitalisation the key to efficient EU pharmaceutical… 27 October 2021 "Digitalisation the key to efficient EU pharmaceutical regulation and easing…
EU must take the lead to ensure security of supply for… 16 June 2021 Legislative reforms aligned with current off-patent market conditions are the…
Common Statement: Supporting Statement for the Council… 14 June 2023 As trade associations representing off-patent medicines and Active Pharmaceutical Ingredients…
Essential medicines must be included in EU industrial policy… 3 March 2022 Political ambitions to strengthen EU supply chain resilience following the…

MANUFACTURING CHEMIST – EU supply chain regulation: what will it mean for companies attending CPHI?

17 October 2022

Related Posts